Get the app
Get the app

Join millions of investors on Stash

Investing, simplified

Start today with as little as $5
Get the app
Money News

Marijuana-Derived Epilepsy Drug Gets Green Light From FDA

June 25, 2018

The drug, which contains CBD, will hit shelves later this year.

1 min read

In a first, the U.S. government has given a marijuana-derived drug the green light.

Epidiolex, a medication developed to treat two forms of childhood epilepsy, contains a chemical compound found in the cannabis plant, called cannabidiol (commonly referred to as CBD).

It’s the first time the FDA has approved a drug that contains a substance derived from marijuana.

What you need to know:

What’s CBD?

CBD, the primary chemical component in Epidiolex, comes from the cannabis plant.

CBD has been found to have therapeutic and medical applications and does not have any associated psychoactive effects, unlike its chemical cousin, tetrahydrocannabinol (THC). THC is the psychoactive compound in the plant, which produces the trademark “high”.

In addition to seizures, CBD is used to treat conditions like multiple sclerosis, Parkinson’s disease, and rheumatoid arthritis.

A message from the FDA commissioner:

“This product approval demonstrates that advancing sound scientific research to investigate ingredients derived from marijuana can lead to important therapies,” FDA Commissioner Scott Gottlieb said in a statement.

“The FDA will continue to support rigorous scientific research on potential medical treatments using marijuana and its components that seek to be developed through the appropriate scientific channels,” he added.

What’s next for marijuana and medicine?

The FDA giving Epidiolex the go-ahead for U.S. sales could, however, open the door for other cannabis-derived drugs to also earn government approval. The approval marks a historic first for the U.S. government.

Read more: If Cannabis is Illegal Under Federal Law, How Is It Legal to Invest In It?

Also, the news comes on the heels of the Canadian government’s passage of legislation to legalize marijuana for recreational use nationwide. Several U.S. states have also legalized cannabis, though it’s still federally prohibited.

Want to learn more about companies leading the charge in the marijuana industry? Check out these investments on Stash.

Investing, simplified

Start today with as little as $5

Get the App

By Sam Becker

*Stash does not endorse the illegal use of Narcotics.

Next for you
The Marijuana Business: What You Need to Know

Investment Profile

Bonds Worldwide

An International Bond ETF on Stash

Learn more
Explore more articlesChoose a topic to learn more about
pop culture Retirement market news Technology Careers

This material has been distributed for informational and educational purposes only, represents an assessment of the market environment as of the date of publication, is subject to change without notice, and is not intended as investment, legal, accounting, or tax advice or opinion. Stash assumes no obligation to provide notifications of changes in any factors that could affect the information provided. This information should not be relied upon by the reader as research or investment advice regarding any issuer or security in particular. The strategies discussed are strictly for illustrative and educational purposes and should not be construed as a recommendation to purchase or sell, or an offer to sell or a solicitation of an offer to buy any security. There is no guarantee that any strategies discussed will be effective.

Furthermore, the information presented does not take into consideration commissions, tax implications, or other transactional costs, which may significantly affect the economic consequences of a given strategy or investment decision. This information is not intended as a recommendation to invest in any particular asset class or strategy or as a promise of future performance. There is no guarantee that any investment strategy will work under all market conditions or is suitable for all investors. Each investor should evaluate their ability to invest long term, especially during periods of downturn in the market. Investors should not substitute these materials for professional services, and should seek advice from an independent advisor before acting on any information presented. Before investing, please carefully consider your willingness to take on risk and your financial ability to afford investment losses when deciding how much individual security exposure to have in your investment portfolio.

Past performance does not guarantee future results. There is a potential for loss as well as gain in investing. Stash does not represent in any manner that the circumstances described herein will result in any particular outcome. While the data and analysis Stash uses from third party sources is believed to be reliable, Stash does not guarantee the accuracy of such information. Nothing in this article should be considered as a solicitation or offer, or recommendation, to buy or sell any particular security or investment product or to engage in any investment strategy. No part of this material may be reproduced in any form, or referred to in any other publication, without express written permission. Stash does not provide personalized financial planning to investors, such as estate, tax, or retirement planning. Investment advisory services are only provided to investors who become Stash Clients pursuant to a written Advisory Agreement. For more information please visit